Hossein Hozhabri

Dr. Hossein Hozhabri

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
HHHossein Hozhabri
Hossein Hozhabri
FPfrancesca piceci-sparascio
francesca piceci-sparascio
HSHamidreza Sohrabi
Hamidreza Sohrabi
Leila MousavifarLeila Mousavifar
Leila Mousavifar
René RoyRené Roy
René Roy
Meysam SarsharMeysam Sarshar
Meysam Sarshar
Over the past two decades, there have been two major outbreaks where the crossover of animal Betacoronaviruses to humans has resulted in severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). In December 2019, a global public health concern started with the emergence of a new strain of coronavirus (SARS-CoV-2 or 2019 novel coronavirus, 2019-nCoV) which has rapidly spread all over the world from its origin in Wuhan, China. SARS-CoV-2 belongs to the Betacoronavirus genus, which includes human SARS-CoV, MERS and two other human coronaviruses (HCoVs), HCoV-OC43 and HCoV-HKU1. The fatality rate of SARS-CoV-2 is lower than the two previous coronavirus epidemics, but it is faster spreading and the large number of infected people with severe viral pneumonia and respiratory illness, showed SARS-CoV-2 to be highly contagious. Based on the current published evidence, herein we summarize the origin, genetics, epidemiology, clinical manifestations, preventions, diagnosis and up to date treatments of SARS-CoV-2 infections in comparison with those caused by SARS-CoV and MERS-CoV. Moreover, the possible impact of weather conditions on the transmission of SARS-CoV-2 is also discussed. Therefore, the aim of the present review is to reconsider the two previous pandemics and provide a reference for future studies as well as therapeutic approaches.

4 September 2019 in Genes
Verified
Journal Article
Open access
PDF file
VPValentina Pinna
Valentina Pinna
PDPaola Daniele
Paola Daniele
GCGiulio Calcagni
Giulio Calcagni
LMLucio Mariniello
Lucio Mariniello
RCRoberta Criscione
Roberta Criscione
ALAlessandro De Luca
Alessandro De Luca
The aim of this study was to assess the prevalence and type of congenital heart disease (CHD) and the associated mutation spectrum in a large series of patients with neurofibromatosis type 1 (NF1), and correlate the mutation type with the presence and subgroups of cardiac defects. The study cohort included 493 individuals with molecularly confirmed diagnosis of NF1 for whom cardiac evaluation data were available. CHD was reported in 62/493 (12.6%) patients. Among these patients, 23/62 (37.1%) had pulmonary valve stenosis/dysplasia, 20/62 (32.3%) had mitral valve anomalies, and 10/62 (16.1%) had septal defects. Other defects occurred as rare events. In this NF1 subcohort, three subjects carried a whole-gene deletion, while 59 were heterozygous for an intragenic mutation. A significantly increased prevalence of non-truncating intragenic mutations was either observed in individuals with CHD (22/59, 37.3%) or with pulmonary valve stenosis (13/20, 65.0%), when compared to individuals without CHD (89/420, 21.2%) (p = 0.038) or pulmonary valve stenosis (98/459, 21.4%) (p = 0.002). Similarly, patients with non-truncating NF1 mutations displayed two- and six-fold higher risk of developing CHD (odds ratio = 1.9713, 95% confidence interval (CI): 1.1162–3.4814, p = 0.0193) and pulmonary valve stenosis (odds ratio = 6.8411, 95% CI: 2.6574–17.6114, p = 0.0001), respectively. Noteworthy, all but one patient (19/20, 95.0%) with pulmonary valve stenosis, and 18/35 (51.4%) patients with other CHDs displayed Noonan syndrome (NS)-like features. Present data confirm the significant frequency of CHD in patients with NF1, and provide further evidence for a higher than expected prevalence of NF1 in-frame variants and NS-like characteristics in NF1 patients with CHD, particularly with pulmonary valve stenosis.

14 July 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
RFRosangela Ferese
Rosangela Ferese
MBMonica Bonetti
Monica Bonetti
FCFederica Consoli
Federica Consoli
VGValentina Guida
Valentina Guida
ASAnna Sarkozy
Anna Sarkozy
ALAlessandro De Luca
Alessandro De Luca

1 May 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
HHHossein Hozhabri
Hossein Hozhabri
MTMehrdad Talebi
Mehrdad Talebi
MMMohammad Y. V. Mehrjardi
Mohammad Y. V. Mehrjardi
ALAlessandro De Luca
Alessandro De Luca
MDMohammadreza Dehghani
Mohammadreza Dehghani

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
FSFateme Sefid
Fateme Sefid
MTMasoud Dehghan Tezerjani
Masoud Dehghan Tezerjani
SASamira Asadollahi
Samira Asadollahi
SMSeyed Ali Madani
Seyed Ali Madani
TPTayebeh Pardal
Tayebeh Pardal
MMMohammad Yahya Vahidi Mehrjardi
Mohammad Yahya Vahidi Mehrjardi
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.